Get 40% Off
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Albireo Pharma Inc (ALBO)

NASDAQ
Currency in USD
Disclaimer
44.15
0.00(0.00%)
Real-time Data
Day's Range
43.9944.90
52 wk Range
16.0245.23
Prev. Close
44.25
Open
44.9
Day's Range
43.99-44.9
52 wk Range
16.02-45.23
Volume
0
Average Vol. (3m)
540,924
1-Year Change
-0.9%
Shares Outstanding
20,863,673
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about ALBO?
Vote to see community's results!
or

Albireo Pharma Inc Company Profile

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. was incorporated in 2003 and is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc.

Industry
-
Sector
-
Employees
130
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.